Annexon Inc ANNX

$4.02 +0.02 (0.50%)

Valuation

Market cap
758,316,000
Revenue TTM
$0
Net income TTM
$-206,690,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
2,385,100
Avg volume
2,931,836
Day's range
$3.97 – $4.14
Shares out
189,579,000
Stochastic %K
31%
Beta
1.32
Analysts
Strong Sell
Price target
$15.62

Price

Company profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial fo...

Show more

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 822 5500
Website
https://www.annexonbio.com
Address
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States

Latest news

Stocktwits

Merlintrader Oct 9, 11:18 PM
Annexon $ANNX: ARCHER II, Vision and GBS The Q4 ARCHER II monitoring assessment is not the final readout. The hub explains the vision endpoint, GBS program and financing risks. https://www.merlintrader.com/annexon-stock-hub/
0 replies
Lightening_strikes Oct 9, 8:11 PM
$ANNX can’t hold any modest gains Skepticism is 9.5/10
0 replies
Lightening_strikes Oct 9, 3:17 PM
$ANNX what do we know about Doug love ? Is he a good ceo?
1 replies
Itsybitsybeanbag Oct 9, 12:25 PM
$ANNX 🎶 I can see clearly now this is a POS🎶
3 replies
prismmarketview Oct 8, 7:28 PM
On #WorldSightDay, more than a billion people still lack the eye care they need. This year’s call to #LoveYourEyes puts the focus on making care accessible, available and affordable for everyone. Five public companies are helping move that mission forward. Sight Sciences ($SGHT) is expanding treatment options for glaucoma and dry eye through procedure-based care, including its implant-free OMNI surgical system. STAAR Surgical ($STAA) offers implantable lenses that give patients an alternative to glasses, contacts and laser vision correction. Opus Genetics ($IRD) is developing gene therapies for rare inherited retinal diseases, including a form of childhood blindness. Annexon ($ANNX) is advancing a potential treatment to preserve vision in people living with geographic atrophy. From expanding access to developing new treatments, these companies reflect different approaches to a shared goal: helping more people see a brighter future. #LoveYourEyes #EyeHealth #HealthcareInnovation
1 replies
Itsybitsybeanbag Oct 8, 7:03 PM
$ANNX F’n POS ( note the added…)
1 replies
Sly15 Oct 8, 11:41 AM
$ANNX reverse head and shoulders forming
0 replies
djmojo1485 Oct 7, 7:11 PM
$ANNX At least they only have 2 months left to break out hearts if their timing hold for EMA and P3 data
2 replies